Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Convertible Debt: 2009-2021

Historic Convertible Debt for Northwest Biotherapeutics (NWBO) over the last 9 years, with Dec 2021 value amounting to $300,000.

  • Northwest Biotherapeutics' Convertible Debt changed negligibly% to $300,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $300,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $300,000 for FY2021, which is negligibly% changed negligibly from last year.
  • Northwest Biotherapeutics' Convertible Debt amounted to $300,000 in Q4 2021, which was down 0.00% from $300,000 recorded in Q4 2020.
  • Over the past 5 years, Northwest Biotherapeutics' Convertible Debt peaked at $6.6 million during Q1 2018, and registered a low of $300,000 during Q4 2020.
  • Over the past 2 years, Northwest Biotherapeutics' median Convertible Debt value was $307,500 (recorded in 2020), while the average stood at $307,500.
  • In the last 5 years, Northwest Biotherapeutics' Convertible Debt crashed by 49.61% in 2017 and then grew by 20.27% in 2018.
  • Quarterly analysis of 4 years shows Northwest Biotherapeutics' Convertible Debt stood at $6.0 million in 2017, then rose by 2.29% to $5.2 million in 2018, then reached $300,000 in 2020, then remained steady at $300,000 in 2021.
  • Its last three reported values are $300,000 in Q4 2021, $300,000 for Q4 2020, and $315,000 during Q3 2020.